Drug Profile
Research programme: antifungal ribosomal protein inhibitors - Melinta Therapeutics
Alternative Names: Antifungal therapeutics research programme - Melinta Therapeutics; RX-06Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Rib-X Pharmaceuticals
- Developer Melinta Therapeutics
- Class Small molecules
- Mechanism of Action Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Mycoses in USA
- 07 Oct 2013 Rib-X Pharmaceuticals is now called Melinta Therapeutics
- 27 Sep 2012 Early research in Mycoses in USA (unspecified route)